Loading...
•
Sep 30, 2020
Lexicon Pharmaceuticals Q3 2020 Earnings Report
Lexicon Pharmaceuticals reported its third quarter 2020 financial results and provided a clinical update.
Key Takeaways
Lexicon Pharmaceuticals reported a decrease in revenues to $6.6 million, primarily due to the termination of the alliance with Sanofi in the previous year. Net income was $82.6 million, driven by a gain on the sale of XERMELO. The company is focusing on the advancement of LX9211 and has commenced a Phase 2 study in diabetic peripheral neuropathic pain.
Commenced patient dosing in a Phase 2 study of LX9211 for diabetic peripheral neuropathic pain.
Preparing to commence an additional Phase 2 study of LX9211 in post-herpetic neuralgia.
Reduced outstanding debt by more than 90%, including the elimination of its $150 million secured term loan.
XERMELO U.S. net sales were $6.5 million prior to the completion of its sale to TerSera Therapeutics LLC.
Revenue by Segment
Forward Guidance
Lexicon Pharmaceuticals anticipates several milestones in the near future.
Positive Outlook
- Initiation of a Phase 2 study for LX9211 in post-herpetic neuralgia in Q4 2020.
- Presentation of data from sotagliflozin SOLOIST and SCORED Phase 3 studies at the American Heart Association Scientific Sessions 2020 in Q4 2020.
- Phase 2 study results in diabetic peripheral neuropathic pain expected in Q4 2021.
- Phase 2 study results in post-herpetic neuralgia expected in Q4 2021.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...